Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Stray Dog Becomes the Star of a Wrestling Match
Two Cats Sitting Under an Umbrella Have the Internet Asking One Very Important Question
7-Year-Old Boy Sends Birthday Card to His Dad in Heaven
Hero Chick-fil-A Employee Saves Woman and Baby
Homecoming King Surprises Everyone by Giving His Crown to the Runner-Up
Fisherman Gives Crabs a Spa Day Before Releasing Them Back Into the Ocean
One-Year-Old Goes Viral For Showing Off Impressive Taekwondo Skills
Exhausted and Injured Jaguar Rescued by Brazilian Soldiers
